Genmab A/S (GNMSF)
GNMSF is quoted over the counter, not listed on an exchange. Genmab A/S files reports with the SEC; the numbers below come from SEC filings and from daily closes, each with its source.
Closes: Yahoo Finance daily closes, last bar 2026-11-13.
Profile
| Field | Value |
|---|---|
| Ticker | GNMSF, quoted over the counter |
| SEC CIK | 0001434265 |
| OTC Markets tier | Pink (price source, 2026-11-13) |
| SEC industry code | Pharmaceutical Preparations |
| Business address | 1253 Copenhagen K, Denmark |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 20-F 2026-02-17 |
| Cash and burn | $1.7B cash; operating cash flow $296.5M a quarter. | Report 2025-12-31 |
| Shares outstanding | 642,384,080 (2025-12-31). the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures. | Cover page 2025-12-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte Statsautoriseret Revisionspartnerselskab, Copenhagen, Denmark | PCAOB Form AP 2026-03-24 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | $3.7B | $963.0M | $1.2B | $1.7B | $5.3B | $3.7B | 20-F 2026-02-17 |
| FY 2024 2024-12-31 | $3.1B | $1.1B | $1.1B | $1.4B | $0 | $3.1B | 20-F 2026-02-17 |
| FY 2023 2023-12-31 | $2.4B | $631.0M | $1.1B | $2.2B | $0 | $2.4B | 20-F 2026-02-17 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B4 | 2019-07-19 |
| Latest annual report | 20-F | 2026-02-17 |
| Latest quarterly / interim | 6-K | 2026-11-12 |
Source: SEC EDGAR submissions feed, 573 recent filings. All filings on EDGAR.
The full dossier has every filing, quarterly and annual financials, the health record and a price chart.
Open the full dossier